Pharmaceutical Sixth Element Capital (6EC), a UK based fund manager established to manage investments for the £70 million ($90.4 million) CRT Pioneer Fund (CPF), and the Cancer Research UK Beatson Institute have reached a multi-year agreement with Swiss pharma giant Novartis to progress development of novel RAS inhibitors, discovered by the Institute’s Drug Discovery Unit for hard to treat cancers. 24 October 2019